Genomind presented a poster, “Pharmacogenetics (PGx) Predictors of Methylphenidate Efficacy in Childhood ADHD” at the 25th Annual World Congress of Psychiatric Genetics, October 13–17, 2017 in Orlando, Florida.
Details about the study and a digital copy of the poster can be found below.
Pharmacogenetics Predictors of Methylphenidate Efficacy in Childhood ADHD
A meta-analysis was conducted to evaluate the aggregate body of pharmacodynamics literature in an effort to identify clinically significant predictors of methylphenidate (MPH) response in children. Genetic variants in SLC6A2 (rs28386840 and rs5569), COMT (rs4680), ADRA2A (rs1800544), SLC6A3 (10-repeat VNTR), and DRD4 (4-repeat VNTR) were shown to be potential candidates for predicting MPH efficacy in children with ADHD.
View and download a PDF of the poster abstract used to present the findings of this study.
